BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005;11:8441-8448. [PMID: 16322307 DOI: 10.1158/1078-0432.ccr-05-1646] [Cited by in Crossref: 81] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Lin CH, Li CH, Liao PL, Tse LS, Huang WK, Cheng HW, Cheng YW. Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway. Br J Pharmacol 2013;168:920-31. [PMID: 23004355 DOI: 10.1111/j.1476-5381.2012.02227.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
2 Vundru SS, Kale RK, Singh RP. β-Sitosterol induces G1 arrest and causes depolarization of mitochondrial membrane potential in breast carcinoma MDA-MB-231 cells. BMC Complement Altern Med 2013;13:280. [PMID: 24160369 DOI: 10.1186/1472-6882-13-280] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
3 Nandi D, Cheema PS, Singal A, Bharti H, Nag A. Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1. Front Oncol 2021;11:751271. [PMID: 34900697 DOI: 10.3389/fonc.2021.751271] [Reference Citation Analysis]
4 Liu Q, Xie G, Wang Q, Mo Z, Li C, Ding S, Wang X. Synthesis of chroman-4-one and indanone derivatives via silver catalyzed radical ring opening/coupling/cyclization cascade. Tetrahedron 2019;75:130490. [DOI: 10.1016/j.tet.2019.130490] [Cited by in Crossref: 11] [Article Influence: 3.7] [Reference Citation Analysis]
5 Patel P, Raval M, Airao V, Bhatt V, Shah P. Silibinin loaded inhalable solid lipid nanoparticles for lung targeting. J Microencapsul 2021;:1-24. [PMID: 34825627 DOI: 10.1080/02652048.2021.2002448] [Reference Citation Analysis]
6 Moreira AJ, Ordoñez R, Cerski CT, Picada JN, García-Palomo A, Marroni NP, Mauriz JL, González-Gallego J. Melatonin Activates Endoplasmic Reticulum Stress and Apoptosis in Rats with Diethylnitrosamine-Induced Hepatocarcinogenesis. PLoS One 2015;10:e0144517. [PMID: 26656265 DOI: 10.1371/journal.pone.0144517] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
7 Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother 2021;145:112409. [PMID: 34781148 DOI: 10.1016/j.biopha.2021.112409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers (Basel) 2021;13:5059. [PMID: 34680208 DOI: 10.3390/cancers13205059] [Reference Citation Analysis]
9 Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15(16): 1943-1950 [PMID: 19399925 DOI: 10.3748/wjg.15.1943] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
10 Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol 2007;224:350-9. [PMID: 17184801 DOI: 10.1016/j.taap.2006.11.011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
11 Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett 2010;291:120-9. [PMID: 19900758 DOI: 10.1016/j.canlet.2009.10.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
12 Li Y, Martin RC 2nd. Herbal medicine and hepatocellular carcinoma: applications and challenges. Evid Based Complement Alternat Med 2011;2011:541209. [PMID: 21799681 DOI: 10.1093/ecam/neq044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
13 Jiang Y, Song H, Jiang L, Qiao Y, Yang D, Wang D, Li J. Silybin Prevents Prostate Cancer by Inhibited the ALDH1A1 Expression in the Retinol Metabolism Pathway. Front Cell Dev Biol 2020;8:574394. [PMID: 32984354 DOI: 10.3389/fcell.2020.574394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 2011; 17(18): 2288-2301 [PMID: 21633595 DOI: 10.3748/wjg.v17.i18.2288] [Cited by in CrossRef: 211] [Cited by in F6Publishing: 183] [Article Influence: 19.2] [Reference Citation Analysis]
15 Su CH, Chen LJ, Liao JF, Cheng JT. Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer. J Med Food. 2013;16:778-784. [PMID: 23909904 DOI: 10.1089/jmf.2012.2534] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
16 Imamoto R, Okano JI, Sawada S, Fujise Y, Abe R, Murawaki Y. Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med 2014;7:31-8. [PMID: 24348760 DOI: 10.3892/etm.2013.1391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
17 Duan X, Zhou Q, Wan JMF, Yu ACH. Sonoporation generates downstream cellular impact after membrane resealing. Sci Rep 2021;11:5161. [PMID: 33664315 DOI: 10.1038/s41598-021-84341-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Dhami-Shah H, Vaidya R, Talwadekar M, Shaw E, Udipi S, Kolthur-Seetharam U, Vaidya ADB. Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells. J Ayurveda Integr Med 2021;12:465-73. [PMID: 34353693 DOI: 10.1016/j.jaim.2021.04.007] [Reference Citation Analysis]
19 Okano JI, Fujise Y, Abe R, Imamoto R, Murawaki Y. Chemoprevention against hepatocellular carcinoma. Clin J Gastroenterol 2011;4:185-97. [PMID: 26189518 DOI: 10.1007/s12328-011-0227-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
20 Tai CJ, Jassey A, Liu CH, Tai CJ, Richardson CD, Wong SH, Lin LT. Targeting Autophagy Augments BBR-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA. Cells 2020;9:E908. [PMID: 32276448 DOI: 10.3390/cells9040908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Bakhshi F, Molavi O, Rashidi MR, Shayanfar A, Amini H. Developing a high-performance liquid chromatography fast and accurate method for quantification of silibinin. BMC Res Notes 2019;12:743. [PMID: 31727143 DOI: 10.1186/s13104-019-4774-2] [Reference Citation Analysis]
22 Liao CY, Lee CC, Tsai CC, Hsueh CW, Wang CC, Chen IH, Tsai MK, Liu MY, Hsieh AT, Su KJ. Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma. Biomed Res Int. 2015;2015:840542. [PMID: 26858957 DOI: 10.1155/2015/840542] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
23 Forghani P, Khorramizadeh MR, Waller EK. Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. Cancer Med 2014;3:215-24. [PMID: 24574320 DOI: 10.1002/cam4.186] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
24 Lwin KM, Dee YKS, Linn YH. The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times. J Gastrointest Cancer 2021;52:802-8. [PMID: 33095378 DOI: 10.1007/s12029-020-00540-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J 2013;15:707-16. [PMID: 23588585 DOI: 10.1208/s12248-013-9486-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
26 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
27 Delmas D, Xiao J, Vejux A, Aires V. Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity. Molecules 2020;25:E2009. [PMID: 32344919 DOI: 10.3390/molecules25092009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
28 Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol 2015;21:49-59. [PMID: 25834802 DOI: 10.3350/cmh.2015.21.1.49] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
29 Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010;29:447-63. [PMID: 20714788 DOI: 10.1007/s10555-010-9237-0] [Cited by in Crossref: 149] [Cited by in F6Publishing: 129] [Article Influence: 12.4] [Reference Citation Analysis]
30 Dhami-Shah H, Vaidya R, Udipi S, Raghavan S, Abhijit S, Mohan V, Balasubramanyam M, Vaidya A. Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis. Clin Mol Hepatol 2018;24:77-87. [PMID: 29254285 DOI: 10.3350/cmh.2017.0039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
31 Qiu GH, Xie X, Xu F, Shi X, Wang Y, Deng L. Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology 2015;67:1-12. [PMID: 25002206 DOI: 10.1007/s10616-014-9761-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
32 Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif. 2009;42:229-240. [PMID: 19317806 DOI: 10.1111/j.1365-2184.2008.00581.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
33 Cheng KC, Asakawa A, Li YX, Chung HH, Amitani H, Ueki T, Cheng JT, Inui A. Silymarin induces insulin resistance through an increase of phosphatase and tensin homolog in Wistar rats. PLoS One 2014;9:e84550. [PMID: 24404172 DOI: 10.1371/journal.pone.0084550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
34 Koltai T, Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J Evid Based Integr Med 2022;27:2515690X211068826. [PMID: 35018864 DOI: 10.1177/2515690X211068826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]